Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
Updated Arfinn Med Scheduler
As your practice begins to grow, it’s important that your booking system is able to keep up. That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform. This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More 
PTSD and Cannabis
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that occurs in people who witnessed or have gone through a traumatic event. That can include events such as natural disasters, war/combat, a serious accident, or personal assault, among others. People suffering from PTSD have disturbing thoughts and feelings related to the traumatic event that can last…
Read More 
PTSD: Is There Any Relief?
In honor of PTSD awareness month, let’s take a look at the debilitating mental health condition and how medical marijuana could help.Post-traumatic stress disorder is a mental health condition caused by witnessing or experiencing a traumatic event. It is understandable for one to be taken aback and impacted by a traumatic event, but if specific…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
The Lack of Clinical Trials in the Medical Marijuana Industry
As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical…
Read More 
Doctors and patients are flying blind as medical marijuana use rises, research lags
Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to…
Read More